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Background: Tumor necrosis factors, TNF and lymphotoxin-α (LT), are cytokines that bind to two receptors, TNFR1
and TNFR2 (TNF-receptor 1 and 2) to trigger their signaling cascades. The exact mechanism of ligand-induced
receptor activation is still unclear. It is generally assumed that three receptors bind to the homotrimeric ligand to
trigger a signaling event. Recent evidence, though, has raised doubts if the ligand:receptor stoichiometry should
indeed be 3:3 for ligand-induced cellular response. We used molecular dynamics simulations, elastic network
models, as well as MM/PBSA to analyze this question.
Results: Applying MM/PBSA methodology to different stoichiometric complexes of human LT-(TNFR1)n=1,2,3 the free
energy of binding in these complexes has been estimated by single-trajectory and separate-trajectory methods. Simulation
studies rationalized the favorable binding energy in the LT-(TNFR1)1 complex, as evaluated from single-trajectory analysis to
be an outcome of the interaction of cysteine-rich domain 4 (CRD4) and the ligand. Elastic network models (ENMs) help to
associate the difference in the global fluctuation of the receptors in these complexes. Functionally relevant transformation
associated with these complexes reveal the difference in the dynamics of the receptor when free and in complex with LT.
Conclusions: MM/PBSA predicts complexes with a ligand-receptor molar ratio of 3:1 and 3:2 to be energetically favorable.
The high affinity associated with LT-(TNFR1)1 is due to the interaction between the CRD4 domain with LT. The global
dynamics ascertained from ENMs have highlighted the differential dynamics of the receptor in different states.
Keywords: Elastic network model (ENM), Lymphotoxin, MM/PBSA, Receptor, Tumor necrosis factor (TNF)Background
Protein-protein interactions are critical for signaling events
within a cell. An investigation on the precise recognition of
ligands by their respective receptors is an active field of re-
search, since breakdown of such specific recognition is the
root cause of several diseases and infections. One of the ra-
tional motives to understand such phenomena is to develop
antibodies and small-molecule inhibitors that modulate the
outcome of such interactions. One such system that gener-
ated immense attention owing to its central role in inflam-
matory effect, immunological response, but also in several
autoimmune diseases and several pathogeneses is the tumor
necrosis factor (TNF) [1,2]. Two TNF ligands, namely
TNF-α (or TNF) and TNF-β (or lymphotoxin-α, LT) have
been extensively studied to methodologically dissect cellular* Correspondence: kaestner@theochem.uni-stuttgart.de
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distribution, and reproduction in any mediumsignaling and diseases related to their malfunction [3-6]. It
is now well recognized that several cellular responses are
directly dictated by TNFs and about 20 homologous cyto-
kines have been identified [7].
TNF and LT exert their effects by binding to two recep-
tors, TNFR1 and TNFR2 (tumor necrosis factor receptor 1
and 2) [8-10]. TNFRs are type I membrane receptors char-
acterized by 2 to 6 CRDs (cysteine-rich domains) in the
extracellular region of the receptor. Both TNFR1 as well as
TNFR2 contain four CRDs. In solution as well as in their
complex with receptors both TNFs exist as homotrimers
and display similar secondary structure profile [11,12]. Their
secondary structure is predominantly β-sheet with each
monomer consisting of 8 anti-parallel β-strands. The β-
sheets form a double layer, one facing the interior of the tri-
meric complex while the other is exposed to the solvent
and is referred as “jellyroll” β-sheet sandwich. The outer β-
sheet is hydrophilic while the interior sheets are mainlyMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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structure with disulfide bridges between its domains. So far
only the extracellular domain of the receptor, also called the
soluble receptor, has been solved [13]. The X-ray structure
of LT in complex with TNFR1 [12] proved vital in under-
standing how LT is recognized by its receptors. These bind
at the grooves of the monomer-monomer interfaces of LT.
Major contacting regions of TNFR1 lie at CRD2 and CRD3,
see Figure 1. The recently solved X-ray structure of the
TNF-TNFR2 complex [14] opens a new window of oppor-
tunities in this already interesting system. In the absence of
ligands, receptors were found by crystallographic experi-
ments as parallel or anti-parallel dimers [13], with the bio-
logical significance of the antiparallel dimerization mode
being questionable. In the parallel dimer the ligand-binding
domains are exposed to the solvent.
The TNFRs exhibit distinct functional roles and diverse
signaling capabilities. While TNFR1 is expressed in all tis-
sues, TNFR2 is expressed particularly in immune cells and
other specialized cell types like endothelial and neuronal tis-
sue [8,15]. TNFR1 primarily invokes cytotoxic activities of
the cell whereas TNFR2 functions as a receptor for T-cell
signaling and for mediating host infections [16]. In contrast
to TNFR2, TNFR1 contains a death domain in its cytoplas-
mic region and upon ligand binding is capable of activating
the apoptotic pathway [15]. Experimental evidence also sug-
gests only TNFR2 to exhibit differential binding to soluble
and membrane bound TNF-α [17]. Although the two
receptors share good homology in their extracellular do-
main, their cytoplasmic regions show significant differences
in their sequences. Due to their central role in cellular sig-
naling, several diseases are directly linked to the TNF family
of ligands and receptors [18]. Animal models of diseases
have predicted the predominant role of TNFR1 in several
pathogeneses and adverse causes of enhanced inflammationFigure 1 Left: extracellular part of the complex of LT with three
receptors, LT-(TNFR1)3; right: receptor dimer (TNFR1)2. LT is
colored red, the receptors blue. In the dimer complex, the receptor
monomers are colored blue and orange. The locations of the CRDs
of the receptors (color-marked in one receptor) are indicated.[19]. In contrast, TNFR2 has been demonstrated to be
involved in defects related to cell-mediated immunological
response [20]. Anti-TNF antibodies and engineered soluble
TNFRs have been developed for the treatment of rheuma-
toid arthritis and other diseases [21-23].
Interaction of TNF with its receptors imparts a con-
formational change in the receptors that triggers a cellular
response. But the precise mechanism of receptor activa-
tion by their ligand is still under debate. The first proposal
for receptor activation, known as the ligand trimerization
model, emphasizes the ligand to recruit the receptors to
form the final complex with a ligand-receptor molar ratio
of 3:3 [24]. Recent evidence has, however, raised serious
questions on this mechanism of activation of the recep-
tors. One school of thought envisages receptors as dimers
or trimers in the absence of ligand and propose a pre-ligand
assembly domain (PLAD) formed by the association of two
or three receptors at the membrane distal CRD1 domain,
prior to ligand binding [25,26]. Cross-linking experiments
with TNFR1-Fas and TNFR2-Fas also suggest the formation
of homodimers in the absence of a ligand [27]. These
homo-dimers/trimers of receptors then build up to form
cluster-aggregates on the cell surface upon ligand binding
[28,29]. The CRD1 domain has also been shown to be im-
portant for stabilizing the CRD2 domain for efficient ligand
binding [26]. The recent crystal structure of the CD40-
CD154 complex in a 2:3 molar ratio has further hinted that
the stoichiometry of TNF-TNFR complexes may not always
be 3:3 [30]. Also, recent work has indicated that the forma-
tion of a trimer-monomer complex of a ligand trimer-
receptor monomer complex of the TNF family member
TRAIL is quite stable and may be the first step in the for-
mation of the complex [31]. In this work we investigate the
free energy of binding of LT-TNFR1 complexes. The object-
ive of this work is to shed light on the way in which the
receptors bind to the ligand and to estimate the free energy
of binding involved in complex formation.
Results
Molecular dynamics (MD) simulations have been carried
out on the three stoichiometric complexes of LT with
TNFR1, represented as LT-(TNFR1)1/2/3 along with their
individual binding partners, monomeric TNFR1
(mTNFR1), the dimeric receptor ((TNFR1)2) and trimeric
lymphotoxin (LT), each for 35 ns. The residues 28–171 of
each chain of human LTand the residues 15–153 of human
TNFR1 were included in our model. The receptor is made
up of four cystein-rich domains: CRD1 (residues 15–53),
CRD2 (54–97), CRD3 (98–138), and CRD4 (139–153). For
analysis purposes and to have similar number of residues
to those observed in the dimeric receptor (TNFR1)2 (PDB:
1NCF), only the residues 15–150 from TNFR1 were used
in the MM/PBSA calculations and other analysis. Free en-
ergy of binding has been computed by using MM/PBSA
Mascarenhas and Kästner BMC Structural Biology 2012, 12:8 Page 3 of 14
http://www.biomedcentral.com/1472-6807/12/8methodology in single-trajectory and separate-trajectory
methods. The components of free energies, gas-phase ener-
gies, and solvation free energies have been averaged over
1001 snapshots from MD trajectories.
To ascertain the extent of deviation of the structure
from their initial crystallographic conformation and to
demonstrate proper equilibration, the time-dependence
of the root-mean square deviation (RMSD) of Cα atoms
was calculated with reference to the starting X-ray struc-
ture, see Figure 2. Since the terminal residues belonging
to CRD3 and CRD4 domains, residues 134–153 of
TNFR1, show high temperature factors and fluctuate
readily in MD simulations, we omitted them in the
RMSD calculations. All systems but mTNFR1 are well
equilibrated within the simulation time scale. LT-
(TNFR1)1 exhibits only minimal conformational trans-
formation from its starting structure since its RMSD
remains within 0.3 nm indicating it to be the most rigid
among the studied protein-protein complexes. LT-
(TNFR1)2 also follows a similar trend as exhibited by LT-
(TNFR1)1. However, in the last 10 ns of the simulation
there seems to be a slight increase in its RMSD value.
On the other hand the LT-(TNFR1)3 complex exhibits a
higher RMSD value and seems to equilibrate around
0.4 nm. The monomeric mTNFR1 displays a higher
RMSD, which is expected since it is simulated in an un-
bound form and lacks any kind of external stabilization.
The dimeric complex (TNFR1)2 also deviates from its
initial structure by 0.35 nm, similar to LT-(TNFR1)3, and
equilibrates after about 10 ns of simulation.
To assess the dynamics associated with the receptor in
ligand-unbound form, in dimeric form, and as complexes
of different stoichiometries, the root-mean-square fluc-
tuations (RMSF) of the Cα-atoms of the receptors were
calculated, see Figure 3. The mTNFR1, as expected, exhi-
bits relatively high peaks in the RMSF plots along itsFigure 2 The root mean square deviation (RMSD) of the Cα
atoms of the receptor as a function of time.whole length, indicating its strongly fluctuating charac-
ter. The dimer (TNFR1)2 is well stabilized by compari-
son, especially the residues in the CRD1 and CRD4
domains since these are the regions the two receptors
interact with one another. Interestingly there seems to
be immense stabilization even of the CRD2 and CRD3
domains in (TNFR1)2. Hence, the interaction in the
CRD1 and CRD4 domains restrain the fluctuations of
the CRD2 and CRD3 domains. These CRD2 and CRD3
domains of the receptor are the regions that are primar-
ily involved in ligand binding in the LT-(TNFR1)n com-
plexes. Residues 77–81 and 107–114 of TNFR1 reside at
the cleft formed by the interface between the LT mono-
mers [12]. The fluctuations in these binding regions are,
hence, well constrained in the dimer as well as in the
complex compared to the monomeric form of the recep-
tor. Further down we will discuss that Trp-107TNFR1 is
one of the well-buried residues in the complex being
sandwiched between the interface of the two monomeric
ligands. The CRD4 had been claimed to be highly disor-
dered [12,13] correspondingly huge fluctuations are
observed for this region in our study. The later part of
CRD3 and the whole CRD4 domain showed high levels
of mobility in mTNFR1, LT-(TNFR1)2, LT-(TNFR1)3, but
notably not in LT-(TNFR1)1. In fact in LT-(TNFR1)1 the
residues in these regions display a similar profile to that
observed for (TNFR1)2. Hence the immense stability
attained by the CRD4 domains in LT-(TNFR1)1 indicates
a different behavior compared to the LT-(TNFR1)2 and
LT-(TNFR1)3 complexes which will be rationalized in
more detail below.
Naismith and Sprang [32] have classified the structure
of the receptor into two major types of sub-domains,
namely A1 and B2 modules, based on the structural top-
ology and on disulfide bridges. They denoted the recep-
tor to be made up of three A1 and B2 sub-domains each,Figure 3 The root mean square fluctuations (RMSF) of the Cα
atoms of the receptor. Regions with low RMSF indicate high
stability.
Figure 4 The buried surface area of the individual residues of
the receptor in various complexes.
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A1 (55–70), B2 (73–96), A1 (98–114), B2 (117–137), and
A1 (139–153). These authors also relate the structure of
TNFR1 to be similar to a spiral, where the B-modules
correspond to the plates and the A-modules to the bolts
about which they pivot. The dynamic cross-correlation
matrix (DCCM) extracted for the receptors explicate the
relations between these domains. The correlation pat-
terns of mTNFR1, LT-(TNFR1)2, and LT-(TNFR1)3 are
rather similar, but differ strongly from the pattern of LT-
(TNFR1)1 (see Additional file 1: Figure S1). In the former,
the B2 module of CRD2 and the A1 module of CRD3
(residues 73–96 and 98–114, respectively) are highly
correlated. Both these modules are also anti-correlated to
the B2 module (residues 30–52) of the CRD1 domain, to
the CRD4 domain, and to some extent to the A1 module
(residues 15–29) of CRD1. In contrast to LT-(TNFR1)2
and LT-(TNFR1)3, highly correlated fluctuations observed
in mTNFR1 might be an artifact of its high flexibility
since it is present in an unbound form. In mTNFR1, LT-
(TNFR1)2, and LT-(TNFR1)3, the B2 module of CRD2
and the A1 module from CRD3 are highly correlated.
Thus it can be argued that these sub-domains form a
stable motif across these complexes. The loss of correla-
tions in the dimer (TNFR1)2 is not surprising considering
the interaction in this complex happens mainly via the
CRD1 and CRD4 domains. However, the significant
silencing of correlations in LT-(TNFR1)1 further supports
a unique nature of the interaction between the LT and
TNFR1 in LT-(TNFR1)1.
Residues involved in binding
A qualitative measure of the underlying strength of
interaction between two biomolecules can be gained by
measuring the buried surface area of the complex. The
buried-surface area of individual residues of the receptors
in different complexes averaged over the trajectory is
shown in Figure 4. In the LT-(TNFR1)n complexes, residues
in the CRD2 and CRD3 domains are buried while in the
(TNFR1)2 complex residues in CRD1 and CRD4 are buried.
It is not surprising that residues which are highly buried in
the complexes with LT (in the domains CRD2 and CRD3)
are highly exposed in (TNFR1)2. This gives valid proof in
support of the argument that in the parallel form of the
dimer the binding site domains are exposed to the solvent
and can bind the approaching LT-ligands without any
major structural change. In all LT-(TNFR1)n complexes
residues Leu71, Cys72, Arg77, Lys78, and Glu79 of CRD2
are strongly buried. In CRD3, residue Trp107TNFR1 is well
buried and lies almost exactly at the interface between the
chains of LT (at the membrane-proximal part of LT). In
the LT-(TNFR1)1 complex two residues in CRD4, namely
Phe144TNFR1 and Arg146TNFR1, are well buried indicating a
strong interaction between the CRD4 domain and theligand. In the (TNFR1)2 dimer, residues Gln17
TNFR1,
Lys19TNFR1, and His34TNFR1 in the CRD1 region and resi-
due Phe144TNFR1 of the CRD4 domain are well buried.Hydrogen bonding
A good estimation of the polar interaction between two
molecules can be made from estimating the hydrogen-
bonding interaction between them. The hydrogen bond-
ing interaction between the receptors in (TNFR1)2 and
the receptor-ligand complexes in LT-(TNFR1)n were
measured purely based on the following geometric con-
straints using VMD [33]. A distance cutoff of 0.35 nm
between the donor and acceptor with an angle cutoff of
60° in the angle donor-hydrogen-acceptor were defined
to count for a successful hydrogen bonding interaction.
The average number of hydrogen bonding interactions
(per interface) over the trajectories was 25.5 for (TNFR1)2
and 31.4, 25.7, and 27.7 for LT-(TNFR1)1, LT-(TNFR1)2,
and LT-(TNFR1)3, respectively. Hence, the interaction
between the receptor and the ligand is strongest in the
LT-(TNFR1)1 complex while it is pretty similar within all
other complexes.Complex structures and receptor motions
The LT-(TNFR1)3 complex crystallizes as a trimer and
hence one would expect it to be the most stable complex
with minimal fluctuating character. On the contrary, the
analysis performed so far highlights the immense stability
of LT-(TNFR1)1 among the LT-(TNFR1)n. This is interest-
ing considering one recent investigation of the stability of
various stoichiometric complexes of TRAIL-(DR5)n con-
cluded the TRAIL-(DR5)1 complex to be more stable than
the corresponding dimeric and trimeric complexes [31].
Figure 5 shows the starting and the final structures from
MD of LT-(TNFR1)1. It was found that the CRD4 domain
Figure 6 The major interaction sites of CRD4 with LT in the
complex LT-(TNFR1)1. Residues of TNFR1 (left, backbone colored
orange) are drawn as sticks, while those of LT (right, backbone
colored blue) are represented as ball-stick models.
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meric LT to form a stable interaction with its residues.
In order to investigate the residues that contribute to the
interaction between CRD3 and CRD4 of TNFR1 and LT in
the LT-(TNFR1)1 complex, the hydrogen bonding interac-
tions between these were investigated. In about 94% of the
snapshots a hydrogen bond between the side chain of
Tyr86LT and that of Glu147TNFR1 was observed. Residue
Arg146TNFR1 was also observed to interact with several resi-
dues of LT through hydrogen bonding interactions:
Leu125LT-chA, Gln126LT-chA, Glu127LT-chA, and Tyr122LT-chB
where chA corresponds to one chain of LT, chB to the
neighboring chain, see Figure 6. Considering that
Arg146TNFR1 and Glu147TNFR1 are stronger buried in LT-
(TNFR1)1 than in LT-(TNFR1)2 and LT-(TNFR1)3 it is not
surprising that these are involved in strong hydrogen bond-
ing with the ligand. These two hydrogen bonding interac-
tions remain fairly strong throughout the simulation and
contribute significantly to the binding of CRD4 of TNFR1
to LT in the LT-(TNFR1)1 complex. The bending of the
CRD4 domain is further stabilized by a strong internal
hydrogen bond between Glu147TNFR1 and the backbone of
Asn116TNFR1. Initially the distance between the two atoms
Glu147-CδTNFR1 and the peptide-H of Asn116TNFR1 is
1.4 nm. It decreases to about 0.25 nm during the last 20 ns
of the simulation indicating the strong interaction between
the two residues. Arg146TNFR1 and Glu127LT-chA form a salt
bridge. The distance between the two side-chain atoms Cδ
and Cζ, of Arg146TNFR1 and Glu127LT-chA are plotted as
function of time in Figure 7. It is obvious that the distances
remain within the range of a strong salt-bridge.
The CRD4 domain has been observed to fluctuate readily
in these complexes. Hence, to ascertain the motion of this
domain, the distance between the center of LT and the cen-
ter of the CRD4 domains were monitored for the whole
20 ns of one set of production runs (15–35 ns) (Figure 8).
The distances between them fluctuates strongly in allFigure 5 Starting structure (left) and final simulated structure
(right) of LT-(TNFR1)1. LT is shown in red, the receptor CRDs 1 to 4
are colored yellow, green, purple, and blue. The figure demonstrates
the attachment of the CRD4 domain to the LT.complexes except LT-(TNFR1)1. In LT-(TNFR1)2 as well as
LT-(TNFR1)3 the domains move independently from each
other: while one CRD4 of LT-(TNFR1)2 remains at about
2.8 nm distance from LT, the other moves significantly fur-
ther away, to about 3.5 nm. The same holds true for LT-
(TNFR1)3. In LT-(TNFR1)1, however, the CRD4 is immobi-
lized close to LT, at distances between 2.0 and 1.7 nm. To
confirm this result, we ran additional simulations. Within
35 ns each, the CRD4 domains did not attach to LT in LT-
(TNFR1)2 and LT-(TNFR1)3. In two of the three additional
simulations carried out for LT-(TNFR1)1, the CRD4 domain
attached to LT after 14 ns and 24 ns, respectively, confirm-
ing our proposal of the attachment of CRD4 to LT. Only in
one simulation did it not attach within this simulation time.Figure 7 Distance between the peptide-H of Asn116TNFR1 and
Cδ of Glu147TNFR1 as well as Cδ of Glu127LT and Cζ of
Arg146TNFR1 during the simulation. These hydrogen bonds
stabilize the CRD4 at the membrane-proximal part of LT.
Figure 8 The distance between the CRD4 domain of the
receptor (TNFR1) and the center of LT during the simulation in
the three different complex stoichiometries. It can clearly be
seen that CRD4 attaches to LT in LT-(TNFR1)1 while it remains
unbound in LT-(TNFR1)2 as well as LT-(TNFR1)3.
Figure 9 Comparison of the B factors (temperature factors) as
obtained from crystallographic structures (1TNR [12] and 1NCF
[13], respectively) to those obtained from an ENM.
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This explains the distinct role of LT-(TNFR1)1 compared to
the other complexes already found by the alternative ana-
lysis tools. The inability of the CRD4 domain to bind to LT
in LT-(TNFR1)2 and LT-(TNFR1)3 can be explained on the
basis of their structure. The three LT monomers are
arranged in a triangular cone with their narrow ends point-
ing at the membrane. The width of LT at the top site is
about 50 Å while it is only 30 Å at the membrane proximal
region [12]. Hence the space at the bottom of the LT is
quite small (Figure 1). The space on the LT is probably only
adequate to accommodate one CRD4 domain. In LT-
(TNFR1)2 and LT-(TNFR1)3 it may be that the competition
between the CRD4 domains prevents either of them to
bind.
Results from the elastic network model
One of the major drawbacks of MD simulations is that a
system needs to be simulated for long time scales to ar-
rive at a meaningful interpretation of functionally rele-
vant motions. This naturally requires computational time
ranging from weeks to months for systems like the one
studied here. In order to overcome such time-consuming
calculations several coarse-grained computational meth-
ods have been developed. One such model that has
received wide popularity is the elastic network model
(ENM). Several studies have shown the low-frequency
normal modes obtained from ENM to capture the con-
formational transition of several biomolecules which
have been summed up nicely in the following reviews
[34,35]. Hence, ENM is considered a powerful tool to es-
tablish the large-scale motions of proteins. One factor
that dictates the outcome of the ENM is the springconstant for the interacting atoms. Several groups have
explored distinct ways to rationalize their choice of force
constants [36,37]. In this work, as discussed in Methods,
we defined a set of three force constants depending on
the nature of the bonds. It is to be noted that the ENM
was constructed based on the X-ray structures and is,
thus, independent of the results of the MD simulations.
The low-frequency normal modes obtained from ENMs
have been shown to be functionally relevant motions of
the protein in many cases [38]. As a first method of valid-
ation of the results obtained from the ENM, one usually
compares the fluctuating nature of the individual residues
as ascertained from the ENM to that obtained from the
experimental temperature factors (Figure 9). Here, we add-
itionally compare it to the fluctuations found in MD. The
rapidly fluctuating segments of the protein as obtained
from the MD simulation agree well with those obtained
from the ENM. The fluctuations appearing at the CRD1
domains are reduced for (TNFR1)2 compared to LT-
(TNFR1)3. This is expected since CRD1 is the main inter-
action site in (TNFR1)2. The CRD4 domains on the other
hand fluctuate in a similar fashion for the (TNFR1)2 and
LT-(TNFR1)3 complexes in experiment (temperature fac-
tors in the crystal structures). But results from ENM paint
a completely different picture. The CRD4 domains are the
most fluctuating domains of the receptors, corroborating
with our results from MD simulations (Figure 3). One
major difference between MD and ENM, though, is that
the CRD4 domain of the receptor in LT-(TNFR1)1, which
is the least fluctuating LT-(TNFR1)n complex in the MD
simulations, also displays huge fluctuating behavior in
ENM. This can clearly be rationalized by the fact that
CRD4 is immobilized and bound to LT in LT-(TNFR1)1 in
the MD simulations while it is unbound in the ENM at
the crystal structure.
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different states, we now compare the conformational
changes of the receptor in different states as estimated
from the ENM normal modes. This was accomplished by
comparing the overlap of the first 10 vibrational eigen-
modes (Figure 10). The term “overlap” here refers to the
dot product of the two eigenvectors. A high degree of
overlap of the eigenmodes indicates that both proteins
explore a similar conformational space. The RMSD be-
tween residues 15–150 of the receptors in LT-(TNFR1)3
(PDB: 1TNR) and (TNFR1)2 (PDB ID: 1NCF) is just
1.65 Å, indicating little geometrical difference between
these states. Hence one is tempted to speculate that the
receptors in the two forms would exhibit similar con-
formational changes. In contradiction, comparison of
the eigenmodes shows that the global fluctuations of
the receptors are well distinguished in the two forms
(Figure 10). Also between the two ligand-unbound
forms of the receptor, namely, mTNFR1 and (TNFR1)2,
no significant overlap of the eigenmodes was found.
This shows that the global fluctuations of the receptors
do not resemble each other in the monomeric and the
dimeric forms. The corresponding overlap between LT-
(TNFR1)3 and mTNFR1 is also weak, indicating the
ligand-binding to cause completely different receptor-
motions than in both ligand-unbound forms. Comparison
of the overlap between LT-(TNFR1)3 and LT-(TNFR1)2,1
indicates how ligand-binding transforms the receptor to a
diverse range of conformational transformations. The
binding of just one receptor to the ligand improves the
overlap observed for the eigenmodes of the receptors
to LT-(TNFR1)3. The binding of the second receptor
improves this correlation even more. A very high degree
of overlap is observed for the first two eigenmodes ofFigure 10 Overlap between the first 10 eigenmodes of the receptor in
obtained from an ENM. Strong overlap indicates similar receptor dynamics.LT-(TNFR1)2 and LT-(TNFR1)3. The third eigenmode
from LT-(TNFR1)3 overlaps with the the forth eigen-
mode of LT-(TNFR1)2 and vice versa (Figure 10). Since
the lowest-frequency normal modes are the most signifi-
cant functional motions of the protein, the high degree
of overlap between LT-(TNFR1)2 and LT-(TNFR1)3
shows that the dominant motions of the receptors are
similar in these two complexes. These results give an
overall perspective of the difference in receptor’s func-
tional motions upon ligand binding.
A correlation analysis clearly shows the difference between
the two ligand-free forms of the receptors (Figure 11). The
anti-correlated regions observed for mTNFR1 are somewhat
diminished for (TNFR1)2. For example the anti-correlations
observed between residues 15–34, 37–54 and 75–114 are
significantly reduced. Also the anti-correlated motions be-
tween the residues 15–34 and 124–138, visible for mTNFR1,
are completely lost in (TNFR1)2. Another interesting aspect
to be extracted from this comparison is that the strong cor-
relations observed within residues 74–114 in mTNFR1 is
lost in (TNFR1)2. However, the correlations within residues
54–114 in (TNFR1)2 resemble those of the LT-(TNFR1)n
complexes. Thus, the dynamic motions of the CRD2 and
CRD3 domains, which form the ligand-binding domains of
TNFR1, fluctuate in a similar fashion in (TNFR1)2 and LT-
(TNFR1)n. This suggests that the CRD2 and CRD3 domains
in (TNFR1)2 are optimally aligned and fluctuate in manner
that the ligands can easily identify them. From these conclu-
sions it can be speculated that ligands prefer to bind to the
receptor in its dimeric form rather than to monomers. The
receptors in their ligand-bound forms resemble each other
very closely except that the anti-correlations of the CRD2,3
domains with CRD3,4 are somewhat diminished in LT-
(TNFR1)2 and more so in LT-(TNFR1)3. Also in ligand-different complexed or monomeric states. These data are
Figure 11 The correlation matrix calculated from the 25 lowest-frequency normal modes of the ENM. Top row: mTNFR1, (TNFR1)2 ,
LT-(TNFR1)1. Bottom row: LT-(TNFR1)2, LT-(TNFR1)3.
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prevail within the CRD1 domain as well as within the sec-
ond-half of CRD3 and CRD4 domains. Such correlations are
more strongly observed for LT-(TNFR1)2,3 than for LT-
(TNFR1)1.
The most dominant functional motion as extracted
from the lowest-frequency normal mode of the elastic
network model (ENM) is shown as arrows in Figure 12.
The lengths of the arrows are proportional to the magni-
tude of the fluctuation of the residues. The vectors are
scaled to result in an RMSD of 2 Å between the elonga-
tions in both directions. In all complexes the strongestFigure 12 The dominant functional motions as extracted from the low
atoms of the receptors (purple) and LT (yellow) are shown. The arrows indi
magnitude of displacement from their initial structure in the order blue-gre
LT-(TNFR1)2 top view; right: LT-(TNFR1)3 top view.fluctuations are exhibited by residues of the CRD4 do-
main. The ligand hardly contributes to this motion. The
first mode extracted from LT-(TNFR1)1 is predominantly
a hinge-bending motion. The overall motion drives the
CRD4 domain towards the membrane-proximal center
of LT. Notably, the CRD4 domain exhibits a similar
bending motion in the MD. Hence, the results from the
ENM are in good agreement with the results obtained
from MD. The dominant motions of LT-(TNFR1)2 and
LT-(TNFR1)3 are also concentrated at the CRD4 domains,
but their direction is perpendicular to the direction of
motion observed for CRD4 in the LT-(TNFR1)1 complex.est frequency normal modes obtained from the ENM. Only the Cα
cate the dominant motion. They are colored in the increasing
en-red. Left: LT-(TNFR1)1 side view, membrane at the bottom; middle:
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In this work the formation of LT-(TNFR1)3 was split into
the following three fundamental steps in accordance with
the trimerization model.
Step 1.
LTþ 1 2 TNFR1ð Þ2 ! LT TNFR1ð Þ1

Step 2.
LT− TNFR1ð Þ1 þ 1 2 TNFR1ð Þ2 ! LT TNFR1ð Þ2

Step 3.
LT− TNFR1ð Þ2 þ 1 2 TNFR1ð Þ2 ! LT TNFR1ð Þ3

Our motive for applying the MM/PBSA method on this
system was to shed light on the stability of LT-(TNFR1)n
complexes of different stoichometry. Though precise estima-
tions of binding free energies for protein-protein complexes
are tough, results from MM/PBSA are known to correlate
well with experimental binding free energies [39]. The pre-
cise mechanism for the activation of TNFR1 has been sub-
ject to immense debate. The previous belief of a 3:3 molar
ratio of the ligand-receptor has been hugely influenced by
the first crystallographic structure of the LT-(TNFR1)3 com-
plex. In the recent past, however, evidence and arguments
have been presented that question if indeed that should be
the case. Recently Reis et al. [31] showed for the TRAIL-
DR5 system, a system similar to LT-TNFR1, that the affinity
of DR5 for TRAIL is strongest for the binding of the first re-
ceptor molecule compared to the binding of second and
third, suggesting a ligand-receptor molar ratio of 3:1. An-
other family of TNF-receptor systems, the CD154-CD40,
crystallizes in the molar ratio 3:2 [30]. Hence, it is worth to
analyze if such 3:1 and 3:2 stoichiometric complexes are
stable and plausible for LT-(TNFR1)n. The major advantage
of the MM/PBSA method is its ability to determine free en-
ergies with relatively low computational expense coupled
with the advantage of breaking down the free energy compo-
nents into different energy terms obtained from molecular
mechanics and solvation. Nevertheless, the MM/PBSA ana-
lysis presented here should more be understood as providing
qualitative insight rather than quantitative numbers.Table 1 Binding energies (in kJ/mol) obtained from
single-trajectory analysis
(TNFR1)2 LT-(TNFR1)1 LT-(TNFR1)2 LT-(TNFR1)3
ΔHvdW −671.6 ± 1.2 −739.5 ± 2.2 −600.7 ± 1.7 −670.4 ± 1.9
ΔHelect −668.7 ± 3.5 −676.5 ± 4.3 −567.4 ± 4.6 −662.8 ± 4.2
ΔGpolar 709.3 ± 3.3 700.9 ± 4.0 589.9 ± 2.0 680.4 ± 1.8
ΔGapolar −60.7 ± 0.1 −73.4 ± 0.2 −59.3 ± 0.1 −66.7 ± 0.2
ΔGbinding −691.6 ± 5.0 −788.5 ± 6.3 −637.5 ± 6.4 −719.4 ± 6.2
The actual numbers of the binding energies are certainly too large (too
negative). However, their relative magnitude is more reliable and allows to
draw qualitative conclusions.Results from single-trajectory simulations (SITA)
For the calculation of free energy components of the bind-
ing energy from MD simulations, one needs to extract the
coordinates of the individual binding partners as well as
the complex. It is possible to obtain the coordinates of the
individual proteins from a single simulation of the com-
plex, which is referred as the single-trajectory approach
(SITA). Alternatively, when individual MD runs have been
performed on the individual binding partners and their
complex separately, we refer to them as separate-trajectory
approach (SETA). One major advantage associated withSITA is the reduction in the computational requirement
since only a single simulation of the complex needs to be
performed. But this approach is valid only if the binding
partners do not undergo major conformational and dy-
namic changes upon complex formation. In the present
system, the receptors exhibit huge fluctuations and do-
main movements as discussed above.
The long-range electrostatic interactions hugely influence
protein-protein complexes. Hence accurate estimation of
these influences is eminent in any free energy method. One
usually estimates the accuracy of these calculations based
on the trade-off between the gas-phase electrostatic inter-
action (ΔHelect) and the polar contribution to solvation
(ΔGpolar) obtained from Poissan-Boltzmann (PB) calcula-
tions. The total electrostatic interaction (ΔHelect +ΔGpolar)
is a compromise between the electrostatic energy between
the individual protein in the complex and the cost asso-
ciated with desolvation of the respective proteins. Hence a
positive value indicates the cost of desolvation is higher
than the electrostatic interaction between the binding part-
ners to form the complex. In all the complexes considered
in the present study, it seems that electrostatic interaction
disfavors protein-protein binding. For example, from the
SITA an electrostatic interaction of −668.7 kJ/mol in
(TNFR1)2 is lost due to a higher polar solvation energy of
709.3 kJ/mol, resulting in an unfavorable total electrostatic
interaction of 40.6 kJ/mol, see Table 1. In the same manner
an unfavorable total electrostatic interaction (ΔHelect +
ΔGpolar) of 24.4 kJ/mol, 22.4 kJ/mol, and 17.6 kJ/mol is
found for LT-(TNFR1)1, LT-(TNFR1)2, and LT-(TNFR1)3,
respectively. Hence, from SITA one can conclude that the
polar contributions to the free energy only disfavors inter-
action between the two binding partners. The apolar con-
tribution to solvation free energy (ΔGapolar) on the other
hand is favorable across these complexes. The van der
Waals interaction between the proteins (ΔHvdW) is very
high in all these complexes indicating that such non-polar
interactions contribute majorly to complex stability. There-
fore it is safe to conclude that the total non-polar compo-
nents contribute favorably towards binding free energies
Mascarenhas and Kästner BMC Structural Biology 2012, 12:8 Page 10 of 14
http://www.biomedcentral.com/1472-6807/12/8while the overall electrostatic term disfavors complex
formation.Results from separate-trajectory simulations (SETA)
We have additionally used the SETA method to calculate
the total free energy of binding in these complexes. There
are two ways one can extract the energy components of
TNFR1, either from TNFR1 or from (TNFR1)2. (TNFR1)2
was chosen since crystal structures suggest receptors to
exist as dimers in the absence of ligand. Table 2 shows the
components of the free energy obtained from separate-
trajectory simulations. In all complex formations except
that of LT-(TNFR1)2 the internal energy obtained from the
force field is negative, i.e., binding of two receptors to LT
is favorable while binding of one and three receptors to LT
is not. This can be explained by the unfavorable conform-
ational strain caused by the bending of the CRD4 of
TNFR1 towards LT in LT-(TNFR1)1. In LT-(TNFR1)2, the
binding of the second receptor relaxes the strain since
both CRD4 domains of TNFR1 are unbound again.
The free energy of binding, ΔGgas+solv, estimated from
SETA for LT-(TNFR1)1, LT-(TNFR1)2 and LT-(TNFR1)3,
is −116.8, −119.0 and −86.2 kJ/mol, respectively. The
electrostatic interaction between receptor and ligands is
quite high for these complexes. However, the total elec-
trostatic interaction (ΔHelect + ΔGpolar), which is the sum
of the contribution of electrostatic interaction between
the binding partners and the solvation energy, gives a
true picture of the electrostatic interaction between the
proteins in the complex. The values for the steps 1 to 3
in this investigation are 27.3, −39.7, and 9.3 kJ/mol.
Hence, binding of the second receptor to LT is electro-
statically favorable in contrast to binding of first and
third receptors. The non-polar interaction between the
receptor and the ligand is negative; for the binding of
second receptor the value is comparatively less pro-
nounced. All this suggests that the binding of second re-
ceptor imparts a significant change to LT-(TNFR1)1.
A range of forces and constraints are at play when two
proteins interact to form a complex. The conformationalTable 2 Binding energies (in kJ/mol) obtained from SETA
Step 1 Step 2 Step 3
ΔHint 94.4 ± 4.1 −44.3 ± 4.6 110.0 ± 4.9
ΔHvdW −202.2 ± 5.0 −21.4 ± 6.3 −169.7 ± 6.9
ΔHelect −434.2 ± 12.5 −183.0 ± 13.4 −257.6 ± 13.5
ΔGpolar 461.6 ± 11.0 143.3 ± 11.7 267.0 ± 11.8
ΔGapolar −36.4 ± 0.3 −13.6 ± 0.3 −36.0 ± 0.2
ΔGsolv 425.2 ± 11.0 129.7 ± 11.7 231.1 ± 11.8
ΔGgas+solv −116.8 ± 17.9 −119.0 ± 19.4 −86.2 ± 19.8
The actual numbers of the binding energies are certainly too large (too
negative). However, their relative magnitude is more reliable and allows to
draw qualitative conclusions.freedom of the individual binding partners varies be-
tween the complex and their free form. A parameter that
reflects conformational restrain is the change in the in-
ternal energy. When this parameter is positive it indi-
cates the binding partners have to be conformationally
constrained to form the complex while a negative value
indicates that the conformational restrains on the indi-
vidual binding partners have been relaxed. For steps 1
and 3 the ΔHint values are positive while for step 2 it is
negative, indicating that binding of two receptors to the
ligand is favored. The association of two capable binding
partners occurs invariably at the cost of entropy. En-
tropic changes are hard to estimate in MM/PBSA. How-
ever, in our case in each of the three steps the receptor
from free solution binds to the ligand. The major contri-
bution to entropy arises then from the loss in entropy of
the receptor from its state free in solution to the state
bound to the ligand. Since we mainly compare the free
energies of the different stoichiometric complexes, the
entropy contribution arising from this step should then
be comparable and cancels in the differences. For this
reason we have ignored entropic contributions in the
free energy calculations. The free energy of binding
(ΔGgas+solv) values obtained from our study suggest a
stoichiometric ratio 3:1 and 3:2 are of similar stability
and are little higher in comparison to a 3:3 complex, sug-
gesting such complexes are energetically feasible.
Discussion
In this work, we tried to judge using MM/PBSA method-
ology if LT-(TNFR1)n=1,2,3 complexes can form with a
ligand-receptor molar ratio of 3:1 and 3:2. The exact
mechanism of receptor activation is still unknown. In ac-
cordance with the ligand trimerization model, the free
energy of binding involved in the sequential binding of
the receptors has been estimated. Using an ENM the glo-
bal fluctuations that are associated with these complexes
have been investigated. The results from MD simulations
of the three stoichiometric complexes of the receptor
with LT reveal that the CRD4 domain is attached to LT
and stabilized in LT-(TNFR1)1 while it exhibits extensive
fluctuations in the other two complexes. The low-
frequency normal modes as observed from ENM analysis
display highly symmetric motions of the three CRD4
domains in the LT-(TNFR1)3 complex. A direct impact
of these motions on the cytoplasmic domains can be
postulated. It has been recently proposed that six Fas
intracellular death domains come in close proximity for
inducing the formation of the oligomeric complex of Fas
molecules [40]. Motions as observed in our ENM might
be necessary and appropriate for aligning the intracellu-
lar domains in a systematic fashion and with right steric
requirements to activate the signaling cascade. Such do-
main motions in tandem can change between an
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domains to correct proximity, and a moderately active or
inactivate state, where such proximity between the intra-
cellular domains is either partially or completely lost.
In accordance with TRAIL-DR5[31], we observed that
LT-(TNFR1)1 complex is stable, which is proposed to arise
from the binding of the CRD4 domain to LT. We observed
that only in the LT-(TNFR1)1 complex, the CRD4 domain
binds to LT. Three residues, namely Phe144, Arg146, and
Glu147 have been determined to be crucial for such an
interaction. If such an interaction leads to a stable LT-
(TNFR1)1 complex, as predicted from our MM/PBSA
studies, it opens the debate if the LT-(TNFR1)1 complex
represents an inactive state of the receptor. While LT-
(TNFR1)1 would be inactivate the binding of subsequent
receptors could lead to its activation. Our results from
ENM indicate quite similar domain motions of the recep-
tors in LT-(TNFR1)2 and LT-(TNFR1)3 which differ from
those in LT-(TNFR1)1.
The results of the free energy of binding, ΔGgas+solv,
estimated from MM/PBSA from single-trajectory ana-
lysis reveal the LT-(TNFR1)1 complex to be the most
stable among LT-(TNFR1)n=1,2,3 while that from separate-
trajectory analysis suggest LT-(TNFR1)n=1/2 to be equally
stable. Although both methods utilize the same complex
trajectory as input, only in SETA does one include the
coordinates of ligand and protein in their unbound form
from independent simulations. Since the receptors
undergo a huge conformational change upon complex
formation, the results from SETA should be more trust-
worthy. Several factors have a direct effect on the results
of MM/PBSA, which include the force-field used, simula-
tion time, charge models, solute dielectric constant and
the surface boundary [41-43]. While the actual numbers
obtained may be too high, their relative magnitude is
expected to be more reliable. Estimation of free energies
of binding for a protein-protein complex is a tedious task.
Two major bottlenecks need to be overcome in such
simulations, sufficient sampling and accurate estimation
of entropy. The energy values obtained from this study
are from 20 ns of data which we believe are a good
compromise between size of the system and the number
of simulations that needs to be undertaken coupled
with the corresponding computational cost. The object-
ive of this investigation was to get a hint whether ligand
binding in a sequential fashion, as in steps 1, 2, and 3
leading to the final 3:3 complex strengthens or weakens
the protein-protein interaction. The absolute numbers
might not be that relevant but their relative values aid
in better understanding of the interaction of the
protein-protein complexes in different stoichiometry. In
that sense our free energy results suggests both LT-
(TNFR1)1 and LT-(TNFR1)2 to be more stable than LT-
(TNFR1)3.Conclusion
The present study provides new insight into the LT-
(TNFR1)n complexes. The CRD4 domain of the receptor
in the LT-(TNFR1)1 complex was observed to bind to
LT. With the aid of ENM models the functional motions
exhibited by LT-TNFR1 complexes have been portrayed.
Our analysis suggests the CRD4 to exhibit a kind of zig-
zag motion in LT-(TNFR1)2 and LT-(TNFR1)3 but to be
well immobilized in LT-(TNFR1)1. The low-frequency
normal modes derived from ENM analysis also support
the CRD4 domain to be involved in highly fluctuating
motions. Our free energy results based on MM/PBSA
calculations on single-trajectory and separate-trajectory
support the proposal of stable LT-(TNFR1)1 and LT-
(TNFR1)2 complexes.Methods
System setup
We model the interactions of LT with TNFR1. The start-
ing structure for our simulation was the crystallographic
structure of the human LT-(TNFR1)3 complex (PDB ID:
1TNR) [12] and the receptor dimer (TNFR1)2 (PDB ID:
1NCF) [13]. Other structures for the simulations, LT,
TNFR1, LT-(TNFR1)1, and LT-(TNFR1)2 were extracted
from the trimeric complex structure of LT-(TNFR1)3. All
simulations were performed with GROMACS (ver. 4.0.7)
[44] using the Gromos 43a2 (united-atom) force-field
[45]. The proteins were placed such that a minimum dis-
tance of 0.7 nm is ensured between any sides of the do-
decahedral unit cell and protein atoms. Proteins were
then solvated in water modeled as simple point charge
(SPC) [46]. To preserve electro-neutrality Na+ or Cl– ions
where added when necessary. The whole setup was energy
minimized, first with steepest decent followed by conjugate
gradient. As the first step in molecular dynamics, random
velocities were generated at 300 K. Keeping the heavy atoms
of the protein restrained with a force constant of
1000 kJ mol-1 nm-2, the solvent molecules were allowed to
equilibrate for 30 ps. The restraints were then removed and
system was further allowed to equilibrate at 300 K for an-
other 1 ns. The simulation was then extended to 35 ns of
MD run. The temperature was maintained at 300 K using
the Berendsen thermostat [47] with a coupling constant of
0.1 ps. Protein and solvent were independently coupled to
the reference temperature. In the first equilibration phase a
Berendsen barostat was used while in the subsequent MD
run Parrinello–Rahman [48] pressure coupling (with a
coupling constant of 1 ps) was applied. Short-range non-
bonded interactions were cut off at 1.2 nm. Electrostatic
interactions above this range were evaluated using PME.
The pair list was updated every 5 steps. All bonds were con-
strained using the LINCS algorithm [49] permitting an inte-
gration time step of 2 fs.
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MM/PBSA (Molecular Mechanics/Poisson-Boltzmann
Surface Area) is one of the simplest and yet most widely
accepted free-energy estimation method. MM/PBSA com-
bines molecular mechanics energies and continuum solvent
approaches to predict free energies of binding [50]. The
method has found widespread use since its introduction
more than a decade ago. It has also been applied to pro-
tein-protein complexes [39]. According to this approach,
the free energy of binding (ΔGbinding) may be evaluated as
ΔGbinding ¼ ΔGcomplex–ΔGprotein–ΔGligand ð1Þ
where each individual term on the right hand side of equa-
tion (1) is made up of the following terms,
G ¼ Hgas þ Gsolv–TS ð2Þ
Gsolv ¼ Gpolar þ Gapolar ð3Þ
Hgas ¼ Hint þHvdW þ Eelect ð4Þ
Hint ¼ Hbond þHangle þHdihedral ð5Þ
In the above expressions Hbond, Hangle, and Hdihedral are
the contributions to internal energy (Hint) obtained from the
components of potential energy of the force field. The en-
ergy terms HvdW and Helect are van der Waals and electro-
static interaction energy, respectively. Helect was computed
using the coulomb module of the APBS software [51]. The
HvdW energies were computed fully, i.e., without either peri-
odic boundary conditions or cutoff using GROMACS. The
free energy contribution from solvation (Gsolv) is estimated
from the polar (Gpolar) and apolar (Gapolar) contributions to
the solvation. The energy terms are averaged over 1001
equally spaced snapshots extracted from the last 20 ns of the
molecular dynamics trajectory. VMD version 1.9 was used
for visualization and for the hydrogen bond analysis [33].
The electrostatic component of the solvation free
energy Gpolar, resulting from the Poisson-Boltzmann
equation, was calculated with the program APBS. In this
study the PARSE parameters were used [52]. The interior
relative dielectric constants of the protein and the solv-
ent dielectric were set to 2 and 78.54, respectively. The
van der Waals surface was used for the dielectric bound-
ary. 225 grid points in each direction and a grid spacing
of 0.5 Å were used for all calculations. No counterions
were included for the calculation. The non-polar contri-
butions to solvation were estimated from the solvent
accessible surface area (SASA), Gapolar ¼ γSASAþ b ,
where γ = 0.0227 kJ mol-1Å-2, b = 3.85112 kJ mol-1 [52].
The SASA of the solute molecules were calculated using
APBS. The objective of the study was to compare the
free energies of the different stoichiometric complex.
Since estimating entropy contribution to binding in a
protein-protein complex is a challenging task, especiallyfor a protein of this size we have ignored entropy contri-
butions to free energy.
Elastic Network Model (ENM)
Coarse-grained elastic network models (ENM) have gained
enormous attention in the past decade to study the intrinsic
motions of a protein [34]. Two commonly used ENM models
are the Gaussian network model (GNM) [53] and the aniso-
tropic network model (ANM) [54]. In this work we used an
ANM to extract the functionally relevant motions exhibited
by the protein. In a conventional ANM analysis, only the Cα
atoms are considered and connections between them are
defined based on a cutoff. In this study we have incorporated
few extensions to this general approach. (a) In addition to the
Cα atoms the side chains of the residues were also included
in this model at a coarse-grained level. Hence, for every resi-
due (except for glycine) two nodes have been defined, one at
the Cα and the other at the center of mass of the heavy atoms
of the side chain. A similar strategy has been previously
adopted on the chaperonin GroEL [55]. For the residues ASP,
ASN, ARG, LYS, GLN, and GLU, which have their interaction
center primarily at the terminus of the side chain, we used the
Cγ, Cγ, Cζ, Nζ, Cδ, and Cδ positions, respectively, instead of
their side chain center. (b) Several types of force constants
have been assigned between atoms depending on their bond-
ing criteria or distance. A side chain node is attached to its
Cα with a force constant of 10 kcal mol-1 Å-2. For atoms that
are within 0.4 nm, between 0.4 and 0.8 nm, and between 0.8
and 1.2 nm, a force constant of 3, 2, and 1 kcal mol-1 Å-2,
respectively, was assigned. Interactions between atoms further
than 1.2 nm apart were ignored. (c) The receptors in this
study possess several disulfide bonds, which act as major
forces that render stability to the receptor. Hence, including
these interactions in ENMs was considered imperative. To
identify these disulfide bridges we used the DSSP program
[56]. A force constant of 10 kcal mol-1 Å-2 was assigned
between the side chain nodes of the two cysteine residues to
mimic the disulfide bridge. (d) Secondary structural informa-
tion was included by raising the force constant between Cα
atoms in the backbone of α-helices and β-sheets to
6 kcal mol-1 Å-2. Structural elements were identified using the
program STRIDE [57]. We calculated the Hessian matrix with
the 'pdbmat' program [58] and the matrix was diagonalized
using Prody [59] to calculate the eigenvalues and eigenvectors
and to perform further analysis related to ENM.
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